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Abstract 
Background: Although anti-malarial medicines are free in Kenyan public health facilities, patients often seek treat-
ment from private sector retail drug outlets. In mid-2010, the Affordable Medicines Facility-malaria (AMFm) was 
introduced to make quality-assured artemisinin-based combination therapy (ACT) accessible and affordable in private 
and public sectors.
Methods: Private sector retail drug outlets stocking anti-malarial medications within a surveillance area of approxi-
mately 220,000 people in a malaria perennial high-transmission area in rural western Kenya were identified via a cen-
sus in September 2013. A cross-sectional study was conducted in September–October 2013 to determine availability 
and price of anti-malarial medicines and malaria rapid diagnostic tests (RDTs) in drug outlets. A standardized question-
naire was administered to collect drug outlet and personnel characteristics and availability and price of anti-malarials 
and RDTs.
Results: Of 181 drug outlets identified, 179 (99 %) participated in the survey. Thirteen percent were registered 
pharmacies, 25 % informal drug shops, 46 % general shops, 13 % homesteads and 2 % other. One hundred sixty-five 
(92 %) had at least one ACT type: 162 (91 %) had recommended first-line artemether-lumefantrine (AL), 22 (12 %) had 
recommended second-line dihydroartemisinin-piperaquine (DHA-PPQ), 85 (48 %) had sulfadoxine-pyrimethamine 
(SP), 60 (34 %) had any quinine (QN) formulation, and 14 (8 %) had amodiaquine (AQ) monotherapy. The mean price 
(range) of an adult treatment course for AL was $1.01 ($0.35–4.71); DHA-PPQ was $4.39 ($0.71–7.06); QN tablets were 
$2.24 ($0.12–4.71); SP was $0.62 ($0.24–2.35); AQ monotherapy was $0.42 ($0.24–1.06). The mean AL price with or 
without the AMFm logo did not differ significantly ($1.01 and 1.07, respectively; p = 0.45). Only 17 (10 %) drug outlets 
had RDTs; 149 (84 %) never stocked RDTs. The mean RDT price was $0.92 ($0.24–2.35).
Conclusions: Most outlets never stocked RDTs; therefore, testing prior to treatment was unlikely for customers seek-
ing treatment in the private retail sector. The recommended first-line treatment, AL, was widely available. Although 
SP and AQ monotherapy are not recommended for treatment, both were less expensive than AL, which might have 
caused preferential use by customers. Interventions that create community demand for malaria diagnostic testing 
prior to treatment and that increase RDT availability should be encouraged.
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Background
In Kenya, malaria accounts for more than 20 % percent 
of outpatient visits, 19  % of hospital admissions, 3–5  % 
of hospital deaths and is a leading cause of mortality in 
children less than 5 years of age [1, 2]. The World Health 
Organization (WHO) and Kenya national malaria treat-
ment guidelines recommend prompt diagnosis with a 
parasitological test (i.e., microscopy or malaria rapid 
diagnostic test [RDT]) and treatment with an effective 
anti-malarial medicine as the cornerstone of malaria case 
management [3, 4]. Since 2004, the recommended first-
line artemisinin-based combination therapy (ACT) for 
uncomplicated malaria in Kenya has been artemether-
lumefantrine (AL); AL is provided free in public health 
facilities. However, studies have shown that between 
17–83 % of persons with fever are first treated with medi-
cine purchased from private sector retail drug outlets 
rather than the formal health sector [5, 6]. People seek-
ing treatment from private retail drug outlets are less 
likely to receive anti-malarial medicines recommended in 
the national malaria treatment guidelines [4–6]. In addi-
tion, private retail drug outlets historically have been less 
likely to offer diagnostic testing for malaria prior to sell-
ing anti-malarial medicines to customers, which is con-
trary to national malaria treatment guidelines [4, 7].
An important determinant of prompt and effective 
treatment is the availability of the recommended anti-
malarial medicines in private retail drug outlets. The 
Affordable Medicine Facility—malaria (AMFm) pro-
gramme was introduced on a pilot basis in eight coun-
tries in 2010, including Kenya [7]. The AMFm provided 
quality-assured ACT (QAACT) to wholesalers at a 
heavily-subsidized cost with the objectives of increas-
ing ACT availability, affordability, use and decreasing 
availability (i.e., “crowding-out”) of treatments no longer 
recommended such as sulfadoxine-pyrimethamine (SP), 
chloroquine and oral artemisinin monotherapies [7, 8]. 
The packaging of AMFm-subsidized QAACT is marked 
with a distinctive green leaf logo for easy identification. 
In Kenya, the AMFm subsidy targeted primarily quality-
assured AL in both the public and private sectors. From 
September 2010 to December 2011, the AMFm pilot 
largely met the objectives of increasing availability and 
achieving an initial target price of $0.50 for QAACTs 
to the consumer; the availability increased from 21 to 
60 % in retail drug outlets, and the price decreased from 
a median of $2.63  to $0.58 overall and to $0.46 in rural 
areas [7]. In Kenya, the original AMFm subsidy ended in 
2012. In 2013, AMFm was extended under a revised sub-
sidy scheme, which decreased the subsidy to wholesalers 
and increased the target price of QAACTs to $1.00 to the 
consumer. The target price of $1.00 was across QAACT 
packages for both children and adults.
In 2013, a census was conducted of all private sector 
retail drug outlets in a surveillance area covering approx-
imately 220,000 people in Siaya County, western Kenya, 
as part of a larger study to assess prescribing behaviours 
and knowledge of malaria in pregnancy treatment guide-
lines [9]. Following the census, a cross-sectional survey 
was conducted to determine the availability and price of 
anti-malarial medicines and RDTs in private retail drug 
outlets. Characteristics of the surveyed retail drug out-
lets and personnel and the availability and price of anti-
malarial medicines and RDTs are described.
Methods
Study area
A cross-sectional study was conducted from September 
to October 2013 in the Kenya Medical Research Institute 
and Centers for Disease Control and Prevention’s Health 
and Demographic Surveillance System (KEMRI/CDC 
HDSS) in Siaya County, western Kenya. The HDSS covers 
approximately 700 square kilometres and includes parts 
of three sub-counties, Gem, Siaya and Rarieda, with an 
estimated total population of 220,000 or approximately 
one-fifth of the county population [10]. In 2012, an esti-
mated 38 % of the population in Siaya County was below 
the poverty level and lived on less than $1.25 per day [11]. 
Malaria transmission is perennially high with peaks in 
May–July and October–November coinciding with the 
end of seasonal rains. Overall parasitaemia prevalence in 
the HDSS population was 34.5  % in 2013 (unpublished 
data, Simon Kariuki, KEMRI and Meghna Desai, CDC). 
The HDSS hosts numerous studies on malaria and other 
diseases and has been described in detail elsewhere [10].
Data collection
A census was undertaken to identify all private sector, 
retail drug outlets in the HDSS boundaries; local HDSS 
staff worked with community members and leaders to 
ensure all possible establishments were initially consid-
ered for study inclusion. A private retail drug outlet was 
any registered pharmacy, informal drug shop, general 
shop, homestead or other establishment that sold anti-
malarial medications or malaria RDTs. The type of retail 
drug outlet was categorized by observation and self-
report. Registered pharmacy status was ascertained by 
self-report from the person on duty at the establishment. 
General shops sold medications and other non-health 
related goods. The category of “other” drug outlets 
included mobile vendors, veterinary shops stocking 
human and animal medicines and shops operated by for-
profit community-based organisations. The daily hours 
of operations and patient volume data were reported 
by the person on duty at the establishment. A struc-
tured, standardized questionnaire was administered to 
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proprietors of the retail drug outlets who agreed to par-
ticipate in the survey; data collected included retail drug 
outlet characteristics, availability, type, and pricing of 
anti-malarial medicines and RDTs in stock on the day of 
the survey and within the last 3 months.
Anti-malarial medications and malaria RDTs were 
considered “in stock” if the retail drug outlet had at least 
one unit available for sale to customers on the day of 
the survey. Anti-malarial medicines and malaria RDTs 
were considered “ever stocked” if the retail drug out-
let had sold malaria commodities within the last three 
months. All anti-malarial medicines and RDTs reported 
during the survey were visually verified by study staff; 
artemisinin-based combinations were systematically 
examined for the AMFm logo. All anti-malarial medi-
cine prices were based on an adult-equivalent treatment 
dose unless otherwise indicated. An adult-equivalent 
treatment dose was defined as the number of milligrams 
(mg) of an anti-malarial medicine needed to treat a 
60-kg adult. The local price in Kenya shillings was con-
verted to U.S. dollars using the October 2013 exchange 
rate of 85 Kenya shillings to $1.00. All retail drug outlet 
data were collected via electronic personal data assis-
tants in the field.
Data analysis
Data analysis was restricted to drug outlets that stocked 
any anti-malarial medicine or malaria RDT on the day 
of the survey or within the last 3  months. Data were 
entered, cleaned and analysed using Epi-Info Version 7 
(CDC, Atlanta, GA, USA), Microsoft Access and Excel 
2010 (Microsoft, Seattle, WA, USA) and SAS version 9.2 
(SAS Institute Inc., Cary, NC). Univariate analysis was 
performed to determine the frequencies and proportions 
of the characteristics of retail drug outlets, employees 
and malaria commodities.
Ethics, consent and permissions
A letter stating the purpose of the study was obtained 
from the Siaya County Director of Health. Local HDSS 
staff explained the purpose of the study to drug outlet 
personnel and provided a copy of the letter; verbal con-
sent was obtained in the local language prior to admin-
istration of the questionnaire. No personal identifying 
information was collected from study participants. The 
study was approved by the institutional review boards 
of Kenyatta National Hospital/University of Nairobi 
(#P468/09/2013), Nairobi, Kenya), KEMRI (#2563, Nai-
robi, Kenya) and Liverpool School of Tropical Medicine 
(#13.18, Liverpool, UK). The study underwent human 
subjects review at CDC and was approved as non-
engagement in human subject research.
Results
Retail drug outlet characteristics
The census identified a total of 181 private retail drug out-
lets that stocked anti-malarial medicines within the last 
3 months in the KEMRI/CDC HDSS; 179 agreed to par-
ticipate in the survey and were included in the analysis. 
Among the retail drug outlets, 47 % (n = 83) were general 
shops, 25 % (n = 45) informal drug shops, 13 % (n = 24) 
registered pharmacies, 13  % (n  =  23) homesteads and 
2 % (n =  4) other (Table 1). Drug outlets were open for 
a mean of 12.6 h per day with a range from 6 h in general 
shops to over 17 h in homesteads. Drug outlets served an 
estimated mean of 25.7 and a median of 10.0 customers 
per day (range 1–250). Registered pharmacies served the 
greatest number of customers with an estimated mean of 
74 and a median of 50 customers per day (range 10–250) 
compared to homesteads serving an estimated mean 5.6 
and a median of five customers per day (range 1–10).
Retail drug outlet personnel characteristics
There were a total of 263 employees with an average of 
1.5 (range 1–4) employees per retail drug outlet (Table 1). 
Registered pharmacies had the greatest mean number of 
employees (2.0; range: 1–4), and homesteads had the few-
est (1.1; range 1–2). Overall, 28 % of drug-outlet person-
nel reported completing primary school, 37 % secondary 
school and 33 % had at least some higher education. Reg-
istered pharmacies had the greatest proportion at 40  % 
(n  =  47) of employees with at least some higher phar-
macy-specific education.
Availability of anti‑malarial medicines and RDTs
Table 2 shows the availability of anti-malarial medicines 
and RDTs across retail drug-outlet types. At least one 
ACT, SP and quinine formulations were stocked across 
all retail drug-outlet types. Overall, 92  % (165/179) of 
retail drug outlets stocked at least one ACT. Of the 165 
ACT-stocking outlets 98  % (n =  162) stocked AL; only 
13  % (n  =  22) stocked dihydroartemisinin-piperaquine 
(DHA-PPQ), and 10  % (n  =  16) stocked other forms 
of ACT (i.e., artesunate-amodiaquine or artemisinin-
piperaquine). Among the 201 AL packages at 162 drug 
outlets observed by study staff, 66 % (n = 132) had the 
AMFm logo. Packages of AL with the AMFm logo were 
found across all retail drug-outlet types. Quinine was 
stocked in 34 % (n = 60) of drug outlets; informal drug 
shops (78  %) and registered pharmacies (71  %) were 
most likely to stock quinine. Among the retail drug out-
lets stocking quinine, 62 % stocked the parenteral formu-
lation, 48 % stocked tablets and 32 % stocked suspension. 
SP was stocked in 48  % (n =  85) of retail drug outlets; 
registered pharmacies (75  %) and informal drug shops 
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(76 %) were most likely to have SP. Only 8 % (n = 14) of 
retail drug outlets stocked amodiaquine monotherapy; 
no registered pharmacy stocked it. Artemether paren-
teral formulation for the treatment of severe malaria was 
stocked by 5 % (n = 9) of retail drug outlets, and 25 % 
(n  =  6) of registered pharmacies but no general shops 
or homesteads stocked parenteral artemether. No retail 
drug outlets stocked chloroquine or other artemisinin-
based monotherapy formulations, such as oral or paren-
teral artesunate. Only 10 % (n = 17) of retail drug outlets 
had RDTs in stock at the time of the study; one-third 
(n  =  8) of registered pharmacies stocked RDTs. The 
majority (84 %, n = 149) of retail drug outlets had never 
stocked RDTs.
Table 1 Characteristics of private sector retail drug outlets in Siaya County, Kenya—2013
a N = 175 drug outlets; four removed from analysis due to estimates >3 standard deviations above mean (outliers)
b Total equals slightly less than 100 % due to rounding
c Other category included mobile vendors, veterinary shops stocking human and animal medicines and shops operated by for-profit community-based organisations
Drug‑outlet type Personnel employed Business open  
(hours per day)
Estimated daily customersa
n (%) n Mean Range Mean Range n Mean Range
Registered pharmacy 24 (13.4) 47 2.0 1–4 12.1 9.5–14.5 21 74.0 10–250
Informal drug shop 45 (25.1) 62 1.4 1–2 11.2 7.0–16.0 44 34.4 3–200
General shop 83 (46.4) 123 1.5 1–2 13.1 6.0–16.0 83 15.0 2–100
Homestead 23 (12.8) 26 1.1 1–2 14.2 8.0–17.0 23 5.6 1–10
Otherc 4 (2.2) 5 1.3 1–2 11.6 8.0–15.0 4 12.5 10–20
Total 179 (100.0)b 263 1.5 1–4 12.6 6.0–17.0 175 25.7 1–250
Table 2 Availability of  anti-malarial medicines and  malaria rapid diagnostic tests by  drug-outlet type in  Siaya County, 
Kenya—2013
ACT artemisinin-based combination therapy; AMFm Affordable Medicines Facility-malaria program
a Multiple brands of anti-malarial medications were stocked at some drug outlets
b Data missing for two drug outlets; drug outlets excluded from analysis
Total drug outlets
n = 179
column (%)
Registered  
pharmacies
n = 24
column (%)
Informal drug  
shops
n = 45
column (%)
General shops
n = 83
column (%)
Homesteads
n = 23
column (%)
Other
n = 4
column (%)
Any ACT 165 (92.2) 23 (95.8) 44 (97.8) 73 (88.0) 21 (91.3) 4 (100.0)
 Artemether-lumefantrine 162 (90.5) 22 (91.7) 43 (95.6) 72 (86.7) 21 (91.3) 4 (100.0)
 Dihydroartemisinin- 
piperaquine
22 (12.3) 15 (62.5) 6 (13.3) 1 (1.2) – –
 Artesunate-amodiaquine 12 (6.7) 3 (12.5) 5 (11.1) 3 (3.6) 1 (4.3)
 Artemisinin-piperaquine 4 (2.2) 3 (12.5) 1 (2.2) – – –
Any quinine formulation 60 (33.5) 17 (70.8) 35 (77.8) 2 (2.4) 3 (13.0) 3 (75.0)
 Tablets 29 (48.3) 9 (37.5) 15 (33.3) 1 (1.2) 2 (8.7) 2 (50.0)
 Parenteral 37 (61.7) 12 (50.0) 19 (42.2) 2 (2.4) 1 (4.3) 3 (75.0)
 Suspension 19 (31.7) 4 (16.7) 15 (33.3) – – –
Sulfadoxine-pyrimethamine 85 (47.5) 18 (75.0) 34 (75.6) 20 (24.1) 10 (43.5) 3 (75.0)
Amodiaquine 14 (7.8) – 3 (6.7) 10 (12.0) 1 (4.3) –
Artemether, parenteral 9 (5.0) 6 (25.0) 2 (4.4) – – 1 (25.0)
Artemether-lumefantrine n = 201a n = 28 n = 56 n = 84 n = 29 n = 4
 AMFm green leaf logo 132 (65.7) 20 (71.4) 46 (82.1) 50 (59.5) 13 (44.8) 4 (100.0)
Artesunate-amodiaquine n = 12 n = 3 n = 5 n = 3 n = 1
 AMFm green leaf logo 11 (91.7) 2 (66.7) 5 (100) 3 (100) 1 (100) –
Malaria rapid diagnostic tests n = 177b n = 24 n = 45 n = 82 n = 22 n = 4
 Available on survey day 17 (9.6) 8 (33.3) 5 (11.1) 1 (1.2) 3 (13.6) –
 Never stocked 149 (84.2) 14 (58.3) 34 (75.6) 81 (98.8) 19 (86.4) 1 (25.0)
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Price of anti‑malarial medicines and RDTs
Table  3 shows detailed prices stratified by retail drug-
outlet type. The price of anti-malarial medicines differed 
across retail drug-outlet types and brands of medicine; 
prices were calculated on an adult-equivalent treat-
ment dose for uncomplicated malaria except for par-
enteral formulations, which were per vial. The AMFm 
logo was only identified on two types of ACTs, AL and 
artesunate-amodiaquine. The overall mean price of AL, 
the recommended first-line treatment, was $1.01 and 
median price was $0.94 (range $0.35–4.71). There was 
no significant difference in the mean price of AL with 
the AMFm logo (n  =  132) at $1.01 (range $0.35–3.53) 
compared to without the logo (n =  69) at $1.07 (range 
$0.47–4.71; p  =  0.45). Registered pharmacies had the 
highest mean price at $1.28 and largest price range for 
AL. The recommended second-line ACT, DHA-PPQ, 
was substantially more expensive than AL with an over-
all mean price of $4.39 and median price of $4.14 (range 
$0.71–7.06). Artesunate-amodiaquine was the least 
expensive ACT with an overall mean and median price 
of $0.71 (range $0.59–1.18); all packages of artesunate-
amodiaquine except one had the AMFm logo. Arte-
misinin-piperaquine was the most expensive ACT with 
an average price of $5.53 and median price of $5.47 
(range $5.29–5.88).
The mean price of quinine varied across retail drug-
outlet types and with formulation. The overall mean 
price of quinine tablets was $2.24 (range $0.12–4.71). 
The parenteral quinine formulation per 600  mg/2  ml 
vial had a mean price of $0.48 (range $0.24–1.06). 
The most common quinine paediatric suspension for-
mulation (50  mg/5  ml) had an overall mean price of 
$0.94 (range $0.53–2.35). The overall mean price of 
SP was $0.62 (range $0.24–2.35); SP was most expen-
sive in other outlets and least expensive in general 
shops. The overall mean price of amodiaquine mono-
therapy was $0.42 (range $0.24–1.06) and artemether 
Table 3 Price in  U.S. dollars of  anti-malarial medicines and  malaria rapid diagnostic tests by  drug-outlet type in  Siaya 
County, Kenya—2013
Price per standard adult-equivalent treatment dose for all medicines except parenteral and paediatric suspension formulations
a All prices in U.S. dollars (USD) converted from Kenya Shillings (KES) based on exchange rate in October 2013 (1 USD = 85 KES)
b NA not applicable. Only one price for the medicine formulation; no range reported
c Price analysis for most common formulation only, which represented 87.5 % (21/24) of total
Overall 
median
Overall mean 
(range)
Registered  
pharmacy  
mean (range)
Informal shop 
mean (range)
General shop 
mean (range)
Homestead 
mean (range)
Other mean 
(range)
Price in U.S. dollars ($)a
Artemisinin-based combination therapy
 Artemether- 
lumefantrine
0.94 1.01 
(0.35–4.71)
1.28 
(0.35–4.71)
1.00 
(0.35–2.94)
0.92 
(0.35–1.76)
1.09 
(0.71–1.76)
1.06 
(0.94–1.41)
 Dihydroartemisinin-
piperaquine
4.14 4.39 
(0.71–7.06)
4.38 
(0.71–7.06)
4.45 
(3.53–5.29)
4.12 
(3.53–4.71)
– –
 Artesunate- 
amodiaquine
0.71 0.71 
(0.59–1.18)
0.63 
(0.59–0.71)
0.73 
(0.59–1.18)
0.71 
(NAb)
0.82 
(NA)
–
 Artemisinin- 
piperaquine
5.47 5.53 
(5.29–5.88)
5.61 
(5.29–5.88)
5.29 
(NA)
– – –
Quinine formulations
 Tablets 2.31 2.24 
(0.12–4.71)
2.93 
(1.09–4.71)
1.86 
(0.12–3.53)
2.82 
(NA)
1.62 
(0.59–2.65)
2.35 
(0.88–3.81)
 Parenteral 
(600 mg/2 ml vial)
0.35 0.48 
(0.24–1.06)
0.50 
(0.24–1.06)
0.51 
(0.29–1.06)
0.41 
(0.35–0.47)
0.41 
(NA)
0.33 
(0.29–0.35)
 Paediatric  
suspensionc 
(50 mg/5 ml)
0.82 0.94 
(0.53–2.35)
0.75 
(0.53–0.94)
1.00 
(0.53–2.35)
0.82 
(NA)
– –
Sulfadoxine- 
pyrimethamine
0.47 0.62 
(0.24–2.35)
0.76 
(0.29–1.76)
0.68 
(0.35–2.35)
0.39 
(0.24–0.82)
0.50 
(0.35–0.82)
0.91 
(0.35–1.76)
Amodiaquine  
monotherapy
0.35 0.42 
(0.24–1.06)
– 0.33 
(0.29–0.35)
0.45 
(0.24–1.06)
0.35 
(NA)
–
Artemether, parenteral 
(80 mg/ml vial)
1.18 1.53 
(0.47–4.12)
1.75 
(0.94–4.12)
0.82 
(0.47–1.18)
– – 1.18 
(NA)
Malaria rapid  
diagnostic tests
0.59 0.92 
(0.24–2.35)
1.02 
(0.35–2.35)
0.87 
(0.24–2.35)
– 0.71 
(0.35–1.18)
–
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parenteral formulation (80 mg/ml vial) was $1.53 (range 
$0.47–4.12).
The overall mean price of malaria RDTs was $0.92 
and median price was $0.59 (range $0.24–2.35). Malaria 
RDTs were most expensive in registered pharmacies and 
least expensive in homesteads. The total mean price of 
following national malaria treatment guidelines at a retail 
drug outlet (i.e., diagnosis of uncomplicated malaria with 
an RDT and treatment with AL with the AMFm logo) 
was $1.93 (range $0.59–7.06).
Discussion
The study demonstrates widespread availability of effec-
tive anti-malarial medicines, including the recom-
mended first-line AL, across retail drug outlets in rural 
Siaya County, western Kenya. The mean price of quality-
assured AL with the AMFm logo was consistent with the 
2013 revised target price of $1.00, and quality-assured 
artesunate-amodiaquine with the AMFm logo was priced 
29 % less than the target price to the customer. The data 
demonstrate that the 2013 extension of the AMFm sub-
sidy under the revised scheme has continued the trend 
of increasing availability and affordability of ACT in 
the retail sector as reported by the AMFm Independent 
Evaluation Team in 2012 [7]. The recommended first-
line ACT, AL, was available in over 90 % of drug outlets 
surveyed. In less than 2  years from December 2011 to 
October 2013, ACT availability increased from 60  % to 
over 90  % in retail drug outlets in rural western Kenya 
[7]. Although not part of the AMFm program in Kenya, 
DHA-PPQ is the recommended anti-malarial medicine 
for malaria treatment failures [4]. Treatment failures 
with AL are relatively uncommon in western Kenya, but 
re-infection is common [12, 13]. Only a minority of drug 
outlets stock DHA-PPQ and the price is over four times 
greater than AL; therefore, customers are probably less 
likely to purchase DHA-PPQ as a first-line treatment.
Although no retail drug outlets stocked chloroquine, 
almost half of all drug outlets continue to sell SP for treat-
ment of uncomplicated malaria and a small percentage of 
drug outlets sell amodiaquine monotherapy. On average, 
SP is one-third less expensive than AL, and amodiaquine 
monotherapy is almost two-thirds less. Because SP and 
amodiaquine monotherapy are substantially less expen-
sive than AL, customers might preferentially choose one 
of these non-recommended medications. Evidence from 
neighboring Busia County in western Kenya demon-
strates that when adults are uncertain that malaria is the 
true cause of their illness, they tend to choose the low-
est-priced anti-malarial medicine first from retail drug 
outlets [6]. Use of SP for malaria case management has 
not been recommended in Kenya since 2004 due to wide-
spread resistance [14–16]. Therefore, customers who 
purchase SP are likely to be using an ineffective treat-
ment, which can lead to delays in obtaining the correct 
treatment and increasing the potential for progression 
to severe malaria, particularly in children and pregnant 
women.
In Kenya, SP is recommended only for intermittent 
preventive treatment of malaria in pregnancy (IPTp) in 
malaria-endemic areas, including Siaya County and is 
generally delivered as part of the antenatal care (ANC) 
package [4]. Retail drug outlets might stock SP for sale 
to private health facilities that provide ANC services or 
for women to purchase in the event of SP stock outs at 
public ANC clinics. However, it appears likely that SP is 
being sold to customers for treatment of uncomplicated 
malaria. Riley et al. demonstrated that retail drug-outlet 
personnel sold SP as treatment to 11 % of simulated cli-
ents who asked for treatment due to signs and symptoms 
consistent with malaria, and almost half of retail drug-
outlet providers incorrectly reported that SP could be 
used for treatment [9]. In addition, more drug outlets 
sell SP (48  %) than quinine (34  %), which is the first-
line treatment for malaria in pregnancy during the first 
trimester.
Malaria RDTs are not widely available in retail drug 
outlets in western Kenya. Under current Kenya regu-
lations, only registered pharmacies are licensed to sell 
medications and point-of-service diagnostic testing is not 
permitted. A pilot project to allow pharmacists to con-
duct diagnostic testing with malaria RDTs in registered 
pharmacies, under a Government of Kenya waiver, was 
conducted in three coastal counties in 2014 [17]. Evi-
dence from the pilot suggested that after a package of 
malaria RDT interventions was introduced, the quality 
of malaria RDT services was comparable between private 
health facility providers and registered pharmacists; in 
addition, access and informed demand for malaria test-
ing before treatment led to testing of 90  % of clients in 
both private health facilities and registered pharmacies 
[17]. Data from this and over a dozen other private sector 
malaria RDT pilot projects is informing the discussion of 
changing national policies and regulations to allow point-
of-service diagnostic testing at registered pharmacies in 
Kenya and other malaria-endemic countries to improve 
malaria case management practices [17–19].
However, in this rural western Kenya study area, only 
13 % of private drug outlets were registered pharmacies. 
Policy and regulation changes would only affect regis-
tered pharmacies, which comprise a minority of drug 
outlets where rural communities seek care. As a result, 
customers are unlikely to be tested for malaria prior to 
buying an anti-malarial medicine in drug outlets, which 
is contrary to national treatment guidelines and increases 
the likelihood of over-prescribing [4]. National treatment 
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guidelines recommend parasitological testing prior to 
treatment to improve the rational use of relatively expen-
sive ACT, prevent resistance to artemisinin, and ensure 
patients are promptly and correctly treated for fever-
related illness [4]. Based on significant case management 
improvements when malaria RDTs were introduced into 
registered drug shops in Uganda, Mbonye et  al. devel-
oped policy recommendations to encourage active and 
expanded registration of drug outlets so more drug 
outlets could benefit from potential changes in policy 
and regulation that would allow point-of-service diag-
nostic testing for malaria [18, 20]. Evidence from west-
ern Kenya suggests that drug retailers are interested in 
stocking malaria RDTs because they see the potential for 
increased business and an opportunity to increase both 
retailer and customer confidence in the diagnosis and 
treatment of malaria [21]. Currently, only 10  % of retail 
drug outlets surveyed could offer both malaria RDTs and 
ACT to customers.
In addition, interventions that encourage drug outlets 
to stock and appropriately use malaria RDTs, such as 
training and supervision packages combined with com-
modity subsidies and provider incentives, are likely to 
increase point-of-service diagnostic testing [6, 17, 19, 
22]. In a simulated-client survey conducted in a sample 
of the drug outlets stocking RDTs from this study, only 
17 % of clients were offered an RDT (unpublished data, 
Christina Riley, Emory Rollins School of Public Health). 
However, testing before treatment for malaria is com-
mon in the public health sector throughout Kenya. The 
nationally-representative malaria quality-of-care sur-
vey conducted in September 2014 showed that 91 % of 
public (i.e., Ministry of Health) and non-profit (i.e., non-
governmental organisation or faith-based) facilities had 
either malaria RDTs or functional microscopy services 
available, and 76 % had AL in stock [23]. Among febrile 
patients, two-thirds were tested for malaria; of those 
with a positive malaria test result, 88  % received the 
recommended treatment and only 9  % with a negative 
malaria test received anti-malarial medicines at surveyed 
health facilities [23]. Therefore, the majority of patients 
with malaria who access care in the public health sector 
receive care in line with the national malaria guidelines. 
Strategies that address community trust in the public 
health sector and encourage preferential use of public 
and non-profit health facilities should be considered to 
improve the overall case management of febrile illness 
and malaria.
Conclusions
In Siaya County, western Kenya, the majority of retail 
drug outlets did not stock RDTs in 2013; therefore, test-
ing prior to treatment in accordance with the national 
treatment guidelines was unlikely for customers seek-
ing anti-malarial medicines first in the retail sector. In 
2013, the recommended first-line treatment, AL, was 
widely available across drug-outlet types in rural western 
Kenya. Although SP and amodiaquine monotherapy are 
not recommended for treatment, both were substantially 
less expensive than AL, which might have caused prefer-
ential use by customers. Interventions that increase the 
availability and affordability of malaria RDTs in the retail 
sector and create customer demand for testing prior to 
treatment should be encouraged to improve community 
malaria case management practices.
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